Actively Recruiting
A Multicenter, Randomized Study Evaluating Long-term Benefits of Patient-wide Management Platform in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Led by Qianfoshan Hospital · Updated on 2022-09-08
1268
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are exploring whether using a patient process management platform for managing and following up with patients who have locally advanced or metastatic non-small cell lung cancer (NSCLC) can help extend survival and improve quality of life. NSCLC treatment varies and includes radiation, chemotherapy, targeted therapy, and immunotherapy, but the disease often leads to complications and mental health challenges like anxiety and insomnia. Effective follow-up and management are crucial to addressing these issues and supporting patients through their treatment journey. The study compares two groups: one managed through a whole process follow-up platform where patients can report symptoms, receive reminders for hospital visits and medication, and access educational materials; the other group receives routine follow-up care from investigators or nurses at the hospital. The platform aims to improve treatment adherence, reduce complications, and support psychological well-being. The study is open, randomized, and parallel, conducted across multiple centers. Participants will be monitored up to 96 months for overall survival, progression-free survival, adverse events, follow-up compliance, quality of life, and follow-up satisfaction. Data collection includes patient-reported symptoms and educational engagement via the platform or standard hospital follow-up. Researchers will assess the long-term benefits of this management approach on patient outcomes and experience. The study started in May 2022 and continues until August 2030, with no upper age limit for participants.
CONDITIONS
Brief Title
Patient's Whole Process Follow-up Management(HOPE-1)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully understand the research and voluntarily sign the informed consent form
- Male or female aged 18 years or older at the time of consent
- Diagnosed pathologically or cytologically with non-small cell lung cancer (NSCLC)
- Classified as stage IIB, III, or IV NSCLC according to the 8th edition AJCC
- Not suitable for radical treatment or refuse surgery
- Life expectancy of at least 3 months
- Able to use a smartphone
You will not qualify if you...
- Patients with mental illness
- Presence of any other malignant tumor
- Patients expected to undergo radical surgery
- Currently participating in other clinical trials
- Judged by the investigator as unsuitable to participate in the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 96 months
Participants are observed and followed up over time to collect information on survival, quality of life, adverse events, and compliance with follow-up procedures.
Regular visits depending on cohort assignment and follow-up needs
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China
Actively Recruiting
Research Team
J
Jiandong ZHANG
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here